Ouro Fino Saude Animal Participacoes SA
BOVESPA:OFSA3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Berjaya Corporation Bhd
KLSE:BJCORP
|
MY |
|
Equiniti Group PLC
LSE:EQN
|
UK |
|
Salesforce Inc
NYSE:CRM
|
US |
|
S
|
Scope Fluidics SA
WSE:SCP
|
PL |
|
Supreme Holdings & Hospitality (India) Ltd
BSE:530677
|
IN |
|
Simpson Manufacturing Co Inc
NYSE:SSD
|
US |
|
Gyldendal ASA
OSE:GYL
|
NO |
|
Community Bank System Inc
NYSE:CBU
|
US |
|
KG Petrochem Ltd
BSE:531609
|
IN |
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| BR |
|
Ouro Fino Saude Animal Participacoes SA
BOVESPA:OFSA3
|
1.5B BRL |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
847.5B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
576.1B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.3B USD |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
218.1B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
229.5B CHF |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
156.8B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.6B USD |
Loading...
|
Market Distribution
| Min | -141.6% |
| 30th Percentile | 21.3% |
| Median | 30.7% |
| 70th Percentile | 43.6% |
| Max | 351.5% |
Other Profitability Ratios
Ouro Fino Saude Animal Participacoes SA
Glance View
Ouro Fino Saúde Animal Participações SA engages in the development, production, and sale of veterinary drugs, vaccines, and other products for production and companion animals. The firm manufactures veterinary products using scientific technology in the Company's laboratories. The firm's products are divided into six sectors: Wholesale, Birds, Cattle, Equine, Pet and Pigs. The Wholesale area is divided into four lines: Anti-Mastiticos, producing antibiotics killing bacteria and lumps; Antimicrobial, which focuses on the treatment of bacterial infectious diseases; Ectoparasiticides, concentrated on insect repellent products, and Endectocides, which is the treatment and control of internal and external diseases of cattle, sheep and swine parasites. There is also one additional line of products divided for additives, biological, inoculants, diagnostic kit, probiotics, silage and other supplements, among others.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Ouro Fino Saude Animal Participacoes SA is 51.7%, which is above its 3-year median of 49.2%.
Over the last 3 years, Ouro Fino Saude Animal Participacoes SA’s Gross Margin has increased from 50.7% to 51.7%. During this period, it reached a low of 45.9% on Dec 31, 2023 and a high of 51.7% on Jan 31, 2026.
